Protara Therapeutics, Inc. (TARA), formerly known as Aravive Biologics, Inc., is a clinical-stage company headquartered in New York, USA. It focuses on the development of transformative therapies for patients suffering from cancer and rare diseases with significant unmet medical needs. Protara is dedicated to transcending therapeutic limitations by understanding critical biological pathways, leveraging its deep scientific expertise and capabilities, and driving pre-clinical and clinical development.
Their lead program is TARA-002, an immunotherapy for the potential treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations. TARA-002 is an investigational cell therapy-based treatment, developed from the same master cell bank of the Bacillus Calmette-Guerin (BCG) strain that is used to produce the BCG Live, an immunotherapy for bladder cancer. Currently, TARA-002 is under the investigation in Phase 1 clinical study in pediatric patients with lymphatic malformations. The company plans to initiate a Phase 2/3 clinical trial for NMIBC subject to the completion of the ongoing IND-enabling studies and any FDA feedback.
Another strategic focus of Protara is intratumorally administered OncoVEXmGM-CSF, an oncolytic virus for the treatment of melanoma. It is positioned as an investigational treatment for late-stage melanoma.
Protara not only focuses on ground-breaking treatments in oncology but also has an active interest in treating rare diseases. Its innovative approach to developing its medicines aims to improve prognosis and enhance patients' quality of life while filling the gap in the market's therapeutic needs.
The firm's dedication to advancing treatments for unaddressed diseases has allowed it to emerge as an essential player in the biomedical field. This purpose-driven approach ensures that the industry's needs and the patient's well-being are prioritized. Protara's goal is to uncover scientific breakthroughs and develop revolutionary therapeutic interventions that hold substantial promise to patients with critical unmet medical requirements.
The company's reputation is rooted in scientific integrity and rigorous, transparent processes. Protara brings specific domain expertise, capabilities, and resources to cure patients, whilst strenuously upholding the principles of accountability, ethical conduct, and scientific excellence. The company believes that thriving through scientific innovation is crucial for better therapeutic outcomes and the advancement of medical science. Through their products, Protara Therapeutics is making a notable impact in complex disease treatment, and revolutionizing patient care.